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ABSTRACT
Plasma Epstein-Barr virus (EBV) DNA titers have been used to monitor treatment 
response and provide prognostic information on survival for nasopharyngeal carcinoma 
(NPC). However, the long-term prognostic role of pretreatment and posttreatment 
titers after radical contemporaneous radiation therapy remains uncertain. We 
recruited 260 evaluable patients with non-metastatic NPC treated with radical 
intensity-modulated radiation therapy (IMRT) with or without adjunct chemotherapy. 
Plasma EBV DNA titers at baseline and then 8 weeks and 6 months after IMRT were 
measured. Cox regression models were employed to identify interaction between 
post-IMRT 8th week and 6th month undetectable titers and 3-year survival endpoints. 
Concordance indices (Ct) from time-dependent receiver-operating characteristics 
(TDROC) were compared between patients with post-IMRT undetectable and those 
with detectable titers. After a median follow-up duration of 3.4 years (range 1.4-4.6 
years), patients with post-IMRT 8th week and 6th month undetectable plasma EBV DNA 
titers enjoyed longer 3-year survival endpoints than those who had detectable titers at 
the same time points. Post-IMRT 8th week, and more significantly, post-IMRT 6th month 
undetectable plasma EBV DNA were the only significant prognostic factors of 3-year 
survival endpoints. Ct values for all 3-year survival endpoints for both post-IMRT 8th 
week and 6th month undetectable plasma EBV DNA were significantly higher in those 
with stage IVA–IVB diseases compared to stage I-III counterparts. Early post-IMRT 
undetectable plasma EBV DNA titers were prognostic of 3-year survival endpoints in 
patients with non-metastatic NPC. Intensified treatment should be further explored 
for patients with persistently detectable titers after IMRT.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is unique in its 
geographical distribution with prevalence in Southern 
China, Hong Kong, Taiwan, Singapore and Malaysia as 
well as association with Epstein-Barr virus (EBV) [1, 
2]. According to global cancer registry, NPC ranked 11th 
most common among all malignancies in China in 2008 
with an incidence of 2.8/100000 person-years in men and 
1.9/100000 person-years in females. The most common 
histological types are undifferentiated non-keratinizing 
carcinoma (WHO Type III) and differentiated non-
keratinizing carcinoma (WHO Type II). Radiation therapy 
alone is offered for stage I and II disease while concurrent 
chemoradiation is indicated for locally advanced stage III 
to IVB disease [3]. Intensity-modulated radiation therapy 
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(IMRT) has been the most contemporaneous radiation 
therapy technique for the past decade due to its superior 
tumor coverage and dose sparing of critical normal 
structures from unnecessary radiation, leading to better 
treatment outcomes and toxicity profiles [4-11]. Plasma 
EBV DNA titer has been found important in both diagnosis 
and monitoring of treatment response during and after 
definitive treatment [12-22]. However, its role in the IMRT 
era remains uncertain, and the appropriate time points 
for its surveillance after IMRT are undefined. Currently 
plasma EBV DNA titer has yet to be recommended by 
the American Joint Committee on Cancer (AJCC) staging 
manual and European Society for Medical Oncology 
(ESMO) as a tumor marker in routine clinical staging 
and posttreatment monitoring [23]. There is an unmet 
and urgent need for identifying its role at baseline and in 
posttreatment monitoring to improve risk stratification, 
leading to closer surveillance and intensified treatment in 
poor-risk groups in the modern era of radiation therapy. We 
initiated this prospective observational study on measuring 
baseline and serial plasma EBV DNA titers for all patients 
with newly diagnosed non-metastatic NPC to determine 
the prognostic value of early post-IMRT plasma EBV 
DNA on long-term survival outcomes. We now presented 
our preliminary results on 3-year survival endpoints. 
This study was registered with the National Cancer Trial 
Registry as NCT02476669 (ClinicalTrials.gov).
RESULTS
The study schematic diagram was shown (Figure 1). 
A total of 289 consecutive patients were recruited from 
July 2010 to June 2013. Of them, 29 patients were 
excluded from subsequent analyses after written informed 
consent: 23 patients did not have blood taken for baseline 
or serial plasma EBV DNA, three patients suffered 
from stage IVC metastatic disease confirmed by PET-
CT scan and another three patients died during IMRT 
(two died from sepsis and one committed suicide). The 
characteristics of the remaining 260 patients for analysis 
were displayed in Table 1.
Treatment outcomes after IMRT and their 
plasma EBV DNA at different time points
The median baseline plasma EBV DNA titers for 
all patients was 934 copies/ml (range 10–1575000 copies/
ml). Mood’s median test showed that the medians were 
significantly different across different overall stages 
(P = 0.003) (Figure 2). All patients completed IMRT 
without treatment interruption. Forty-six patients received 
IMRT alone for their early-stage disease (40 patients) 
or because of their advanced age and/or significant 
medical contraindications to chemotherapy (6 patients). 
However, these 6 patients were still free from relapse. 
At 8 weeks after IMRT, 30 patients still had elevated 
plasma EBV DNA (range 14–4512 copies/ml); all but 
1 had undetectable titers at 12 weeks after IMRT and 
this remaining patient’s plasma EBV DNA was then 
undetectable at 16 weeks after IMRT. Another patient, 
despite undetectable plasma EBV DNA, had confirmed 
local persistence at 12 weeks. He received additional 
stereotactic IMRT boost (20Gy in 8 fractions over 1.5 
weeks) without any residual disease noted afterwards. His 
plasma EBV DNA was persistently undetectable before 
and after stereotactic boost. Five patients developed 
progressive disease with distant metastases between 8 
weeks and 6 months after IMRT, and thus they were only 
included in the subsequent TDROC and survival analysis 
using post-IMRT 8th week (but not 6th month) undetectable 
plasma EBV DNA as stratifying factor. Seventeen patients 
had elevated plasma EBV DNA (range 19–29375 copies/
ml) at 6 months after IMRT. Of them, 3 developed local 
recurrence, 1 patient suffered from regional nodal failure, 
5 patients had distant metastases, 1 patient had both 
regional and distant failure, 1 patient had local and distant 
failure and the remaining 6 were still free of relapse. After 
a median follow-up duration of 3.4 years (range 1.4–4.6 
years), 10, 5 and 19 patients had local failure, regional 
failures and distant metastases, translated into 96.2%, 
98.1% and 92.7% for the 3-year local, regional and distant 
metastasis control rates respectively. The 3-year LFFS, 
RFFS, DMFS, PFS, CSS and OS were 95.2%, 96.9%, 
91.2%, 88.0%, 95.8%, 93.9% respectively. The Kaplan-
Meier estimates of all survival endpoints for all stages 
were also shown (Supplementary Figure S1).
Correlation of post-IMRT 8th week and 6th month 
undetectable plasma EBV DNA with long-term 
survival endpoints
Patients who had post-IMRT 8th week and 6th month 
undetectable plasma EBV DNA enjoyed longer 3-year 
survival endpoints compared to those who had post-IMRT 
detectable titers at the corresponding time points, except 
LFFS stratified by post-IMRT 8th week undetectable 
plasma EBV DNA (Table 2, Figure 3 and Figure 4). In 
particular, greater survival differences were revealed 
between patients with undetectable and detectable post-
IMRT 6th month plasma EBV DNA. The prognostic 
significances between post-IMRT 8th week and 6th month 
undetectable plasma EBV DNA and the survival endpoints 
were further evaluated in univariable and multivariable 
Cox models (Supplementary Table S1 to Table S3). Only 
post-IMRT 8th week and 6th month undetectable plasma 
EBV DNA were prognostic of all survival endpoints 
(except for LFFS stratified by post-IMRT 8th week 
undetectable plasma EBV DNA), while baseline plasma 
EBV DNA was prognostic of LFFS, RFFS, DMFS and 
PFS only (Supplementary Table S1 to Table S3).
TDROC analysis revealed significantly higher Ct 
indices and AUC values in stage IVA to IVB diseases 
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Figure 1: Participant flow in the current study. DNA: deoxyribonucleic acid, EBV: Epstein-Barr virus, 18F-FDG: [18F]
fluorodeoxyglucose, IMRT: intensity-modulated radiation therapy, MRI: magnetic resonance imaging, NPC: nasopharyngeal carcinoma, 
PET-CT: positron-emission tomography with integrated contrast-enhanced computed tomography.
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Table 1: Characteristics of study patients
Characteristic
n = 260
No. of patients (%)
Mean age in years (range) 53 (16–91)
Male/female 183 (70.4)/77 (29.6)
ECOG performance status
 0 16 (6.2)
 1 244 (93.8)
T-classification
 T1 77 (29.6)
 T2 28 (10.8)
 T3 115 (44.2)
 T4 40 (15.4)
N-classification
 N0 30 (11.5)
 N1 74 (28.5)
 N2 121 (46.5)
 N3a 4 (1.5)
 N3b 31 (11.9)
Overall stage
 I 17 (6.5)
 II 38 (14.6)
 III 135 (51.9)
 IVA 35 (13.5)
 IVB 35 (13.5)
Laterality of primary tumor
 Midline 142 (54.6)
 Left 57 (21.9)
 Right 61 (23.5)
Retropharyngeal node present 200 (76.9)
Laterality of retropharyngeal node (n = 200)
 Ipsilateral 88 (44.0)
 Contralateral 3 (1.5)
 Bilateral 109 (54.5)
Median baseline plasma EBV DNA in copies/ml (range) 934 (10–1575000)
 Stage I (n = 17) 13 (10–210)
 Stage II (n = 38) 746 (10–21250)
 Stage III (n = 135) 847 (11–175000)
 Stage IVA (n = 35) 1400 (10–90500)
 Stage IVB (n = 35) 7625 (12–1575000)
Radical IMRT only 46 (17.7)
Concurrent chemoradiation 26 (10.0)
Induction chemotherapy then concurrent chemoradiation 89 (34.2)
Concurrent chemoradiation then adjuvant chemotherapy 99 (38.1)
DNA: deoxyribonucleic acid, EBV: Epstein-Barr virus, ECOG: Eastern Cooperative Oncology Group, IMRT: intensity-
modulated radiation therapy.
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compared to stage I to III counterparts for all survival 
endpoints using both post-IMRT 8th week and 6th 
month undetectable plasma EBV DNA as stratification 
(Supplementary Table S4 and Supplementary Figure 
S2). In addition, the Ct indices and AUC values were 
consistently higher for post-IMRT 6th month undetectable 
plasma EBV DNA compared to post-IMRT 8th week 
undetectable plasma EBV DNA. These indicated that post-
IMRT undetectable plasma EBV DNA possessed a higher 
predictive power of survival endpoints for more advanced 
stage disease than earlier stage disease and the power was 
stronger with post-IMRT 6th month undetectable plasma 
EBV DNA than with post-IMRT 8th week undetectable 
titers. This was also illustrated in ordinary ROC analyses 
with, in general, higher AUC values for post-IMRT 6th 
month undetectable plasma EBV DNA in each survival 
endpoint (Supplementary Figure S3).
DISCUSSION
The discovery of plasma EBV DNA has established 
itself as an accurate biomarker for detection, surveillance 
and prognostication of NPC. For the past 15 years, 
numerous studies have investigated the correlation 
between pretreatment plasma EBV DNA levels and 
clinical stage, tumor load and treatment outcomes [12-21]. 
However, either these studies were performed when the 5th 
and 6th edition of AJCC staging system were in use, when 
modern radiation therapy techniques for example IMRT 
was not fully implemented or when various cut-off values 
of pretreatment and posttreatment plasma EBV DNA titers 
were used in the exploratory analyses. In addition, PET-
CT scan as complete and accurate staging workup was not 
employed in previous studies; thus, some patients might 
have been understaged. Though Peng et al in their recent 
Figure 2: Box and whisker plot showing the distribution of baseline plasma EBV DNA titers across different overall 
stages of NPC in the study population. The band inside the boxes indicates the median. The boxes indicate the interquartile range and 
the whiskers indicate the values between (1st quartile - step) and (3rd quartile + step) where step = 1.5 × interquartile range. The * indicates 
an extreme outlier with its value either 2 steps below the 1st quartile or 2 steps above the 3rd quartile. AJCC: American Joint Committee 
on Cancer; DNA, deoxyribonucleic acid, EBV: Epstein-Barr virus.
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Table 2: Impact of undetectable plasma EBV DNA at 8 weeks and 6 months after IMRT on various survival endpoints
Post-IMRT 8th week plasma EBV DNA Plasma IMRT 6th month plasma EBV DNA
0 copies/ml > 0 copies/ml P 0 copies/ml > 0 copies/ml P
LFFS 0.394 < 0.001
 Median (months) NR NR NR NR
 Mean (months) 49.0 47.3 49.4 39.8
 95% CI 48.1–49.9 44.2–50.5 48.6–50.2 32.8–46.8
 HR 0.52 0.10
 95% CI 0.11 to 2.43 0.03-0.37
RFFS 0.034 0.004
 Median (months) NR NR NR NR
 Mean (months) 49.9 47.0 49.9 44.3
 95% CI 49.3–50.4 43.4–50.6 49.3–50.4 38.9–49.7
 HR 0.18 0.11
 95% CI 0.03–0.98 0.02-0.67
DMFS < 0.001 < 0.001
 Median (months) NR NR NR NR
 Mean (months) 48.5 39.0 48.7 32.6
 95% CI 47.4–49.6 32.7–45.3 47.7–49.7 23.9–41.2
 HR 0.14 0.08
 95% CI 0.06–0.36 0.03–0.20
PFS < 0.001 < 0.001
 Median (months) NR NR NR NR
 Mean (months) 47.8 36.7 48.4 25.4
 95% CI 46.6–49.1 30.2–43.2 47.4–49.5 17.4–33.4
 HR 0.16 0.05
 95% CI 0.07–0.35 0.02–0.11
CSS 0.002 < 0.001
 Median (months) NR NR NR NR
 Mean (months) 49.5 44.8 49.7 43.8
 95% CI 48.8–50.3 40.4–49.2 49.1–50.3 39.3–48.4
 HR 0.16 0.11
 95% CI 0.04–0.60 0.03-0.49
OS 0.028 0.004
 Median (months) NR NR NR NR
 Mean (months) 48.8 44.8 49.4 43.8
 95% CI 47.8–49.8 40.4–49.2 48.6–50.2 39.3–48.4
 HR 0.29 0.17
 95% CI 0.09–0.94 0.04–0.67
CI: confidence interval, CSS: cancer-specific survival, DMFS: distant metastasis-free survival, HR: hazard ratio, IMRT: 
intensity-modulated radiation therapy, LFFS: local failure-free survival, NR: not reached, OS: overall survival, PFS: 
progression-free survival, RFFS: regional failure-free survival.
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Figure 3: Kaplan-Meier estimates of all survival endpoints stratified by post-IMRT 8th week undetectable plasma 
EBV DNA. Panel A. shows local failure-free survival. Panel B. shows regional failure-free survival. 
(Continued )
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Figure 3 (Continued ): Panel C. shows distant metastasis-free survival. Panel D. shows progression-free survival. 
(Continued )
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Figure 3 (Continued ): Panel E. shows cancer-specific survival and Panel F. shows overall survival, all stratified by post-IMRT 8th week 
plasma EBV DNA 0 copies/ml and post-IMRT 8th week plasma EBV DNA >0 copies/ml. CI: confidence interval, HR: hazard ratio, IMRT: 
intensity-modulated radiation therapy.
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(Continued )
Figure 4: Kaplan-Meier estimates of all survival endpoints stratified by post-IMRT 6th month undetectable plasma 
EBV DNA. Panel A. shows local failure-free survival. Panel B. shows regional failure-free survival. 
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Figure 4 (Continued ): Panel C. shows distant metastasis-free survival. Panel D. shows progression-free survival. 
(Continued )
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Figure 4 (Continued ): Panel E. shows cancer-specific survival and Panel F. shows overall survival, all stratified by post-IMRT 6th 
month plasma EBV DNA 0 copies/ml and post-IMRT 6th month plasma EBV DNA >0 copies/ml. CI: confidence interval, HR: hazard ratio, 
IMRT: intensity-modulated radiation therapy.
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retrospective study showed the prognostic value of post-
IMRT plasma EBV DNA on survival outcomes, blood 
taking for plasma EBV DNA was checked at only one 
time point after IMRT and the exact date of measurement 
was not specified [24]. On the contrary, our study is the 
first prospective observational studies investigating the 
prognosticative role of baseline and serial post-IMRT 
plasma EBV DNA titers on various predefined survival 
endpoints on the basis of complete PET-CT staging and 
full IMRT implementation.
In addition, the method of measuring plasma EBV 
DNA was in line with that mentioned in the previous 
study be Le et al which correlated the plasma EBV DNA 
titers of 40 samples in each of the four tertiary referral 
centers in the United States, Taiwan and Hong Kong [25]. 
The EBV DNA copy numbers were all determined by 
real-time quantitative polymerase chain reaction (qPCR) 
(BamHI-Wprimer/ probe). A large variabiltiy of plasma 
EBV DNA titers was observed, especially when different 
PCR master mixes and calibrators were used. After study 
harmonization and standardization with the use of same 
master mixes and calibrators, correlations were more 
than 99% between the centers. A uniform and consistent 
method of EBV DNA assay should be employed in future 
multi-center prospective studies.
Our excellent treatment results were likely 
attributed to complete radiological staging, dedicated 
IMRT contouring and planning, and close posttreatment 
surveillance. The median survival was thus not reached 
in all subgroups due to a lack of failure events. This also 
explained why the other prespecified baseline covariates 
including stage and baseline plasma EBV DNA were not 
good segregators of survival difference. Our preliminary 
3-year survival endpoints are also representative indicators 
of long-term survival outcomes, as only 0 (0%), 0 (0%) 
and one (0.4%) patient developed local, regional and 
distant failure respectively at more than three years after 
IMRT. This echoed the large retrospective study in China 
which included 868 patients with non-metastatic NPC 
treated with IMRT with or without adjunct chemotherapy, 
with the vast majority of treatment failures occurring 
within the 1st to 3rd year after treatment [26]. This 
highlighted the crucial importance of frequent surveillance 
within the first three years after IMRT. Of course longer 
follow up with more mature results is needed in our study 
for the detection of late relapses.
Ordinary ROC, as a tool to evaluate the accuracy of 
biomarkers with a contemporaneous reference standard, 
is not robust to predict future events especially survival 
outcomes at a future time point. Instead, TDROC employs 
another reference standard which refers to an event at a 
future time and may not be known for every patient due 
to early censoring [27]. This is particularly favorable to 
predict survival of a highly curable cancer with few failure 
and survival events [28]. We found that, from TDROC 
analysis, higher Ct indices and AUC values were observed 
in stage IVA to IVB diseases compared to stage I to III 
counterparts for all survival endpoints using both post-
IMRT 8th week and 6th month undetectable plasma EBV 
DNA as stratification. In addition, the Ct indices and AUC 
values were consistently higher for post-IMRT 6th month 
undetectable plasma EBV DNA compared to post-IMRT 
8th week undetectable plasma EBV DNA. It could be 
inferred that post-IMRT undetectable plasma EBV DNA 
possessed a higher predictive power of survival endpoints 
for more advanced stage disease than earlier stage disease 
and the power was stronger with post-IMRT 6th month 
than with post-IMRT 8th week undetectable titers. We 
speculated that those with more advanced stage disease 
had higher baseline plasma EBV DNA titers and so post-
IMRT undetectable EBV DNA titers should better reflect 
a higher chance of complete disease remission. Besides, 
5 (1.9%) patients developed progressive disease between 
8th week and 6th month after IMRT and thus only 255 
patients were included in the subsequent time-dependent 
ROC (TDROC) and survival analysis at 6 months after 
IMRT. This might be one possible reason why post-IMRT 
6th month undetectable plasma EBV DNA was more 
predictive of survival endpoints compared to post-IMRT 
8th week undetectable plasma EBV DNA titers.
Our study demonstrated that most treatment failures 
were distant metastases following superior locoregional 
control by IMRT. It may be inferred from our study that 
it is probably not late for patients to consider additional 
intensified treatment at 8 weeks after IMRT if their plasma 
EBV DNA is still detectable, provided that undetectable 
plasma EBV DNA could be achieved at 6 months after 
IMRT. This begs the question as to whether additional 
or more intensified chemotherapy for patients with 
persistently elevated post-IMRT plasma EBV DNA titers 
can reduce distant relapse and improve survival. Twu et 
al demonstrated that adjuvant oral tegafur-uracil for one 
year with or without preceding intravenous chemotherapy 
improved distant relapse and OS in patients with 
persistently detectable plasma EBV DNA taken one week 
after completion of radiation therapy [29]. This has so far 
been the only published study indicating a survival benefit 
of adjuvant chemotherapy in those with persistently 
elevated plasma EBV DNA after completion of RT. 
Recently in the largest multi-institutional prospective 
study in Hong Kong, Hui et al demonstrated that 
posttreatment, instead of pretreatment, plasma EBV DNA 
titers were prognostic of relapse-free survival and OS [30]. 
However, the optimal timing of checking posttreatment 
plasma EBV DNA has yet to be defined since it may take 
longer time for complete clearance of plasma EBV DNA 
after radiation therapy as reported in a previous study 
[31]. Our current study showed that 30 patients (11.5%) 
still had persistently elevated plasma EBV DNA at eight 
weeks after IMRT, but 20 patients had complete plasma 
EBV DNA clearance at later time points without evidence 
of relapse. Moreover, IMRT was not fully implemented 
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in the two aforementioned studies. Whether additional or 
more intensified adjuvant chemotherapy brings survival 
benefit may be deciphered by the ongoing Hong Kong 
NPC-0502 study (NCT00370890), which is designed to 
assess the benefit of adjuvant chemotherapy in patients at 
high risk of disease recurrence, identified with detectable 
plasma EBV DNA at 6 weeks after chemoradiation 
[32]. The combined phase II and III NRG-HN001 trial 
(ClinicalTrials.gov NCT02135042) investigating the role 
of different adjuvant chemotherapy regimens (standard 
cisplatin and 5-FU regimen versus gemcitabine and 
paclitaxel combination) as a phase II setting and omission 
of adjuvant chemotherapy in those with undetectable 
plasma EBV DNA following IMRT may certainly offer a 
clearer answer to this unresolved question [33]. However, 
this will pose another clinical question on the equipoise 
between survival prolongation and chemotherapy-related 
toxicities by the administration of additional adjuvant 
chemotherapy. Chen et al in their phase III multicenter 
randomized-controlled trial concluded that adjuvant 
chemotherapy following concurrent chemoradiation 
failed to improve survival as compared concurrent 
chemoradiation alone [34]. Of note, 82% in the concurrent 
chemoradiation plus adjuvant chemotherapy group started 
adjuvant chemotherapy and only 63% completed all 
cycles of adjuvant chemotherapy. Patient refusal was the 
principal reason for uncompleted adjuvant chemotherapy. 
In addition, 69% and 49% of patients who received 
adjuvant chemotherapy had treatment delays and dose 
reduction respectively, because of adverse events and other 
reasons. The infrequent use of IMRT in less than half of 
the study population was another study limitation. Despite 
lack of improvement in all prespecified survival endpoints, 
numerically the results favored adjuvant chemotherapy 
with a 2% absolute difference in failure-free survival (P 
= 0.13), distant failure-free survival (P = 0.12) and OS. 
Since this study was not designed as a non-inferiority 
trial against concurrent chemoradiation alone, we cannot 
strictly conclude that adjuvant chemotherapy brings no 
benefits in locally advanced NPC. Induction chemotherapy 
before concurrent chemoradiation, on the other hand, 
may improve treatment compliance and possibly better 
systemic control. However, conflicting results were 
reported in different prospective studies [35, 36]. More 
recently, Lee et al in the preliminary analysis of their 
NPC-0501 study revealed that induction chemotherapy 
with cisplatin and capecitabine (PX) reflected a significant 
reduction in the hazards of disease progression and 
possibly death compared to induction chemotherapy with 
cisplatin and 5-FU (PF) and adjuvant PF regimen [37]. As 
a whole, our results suggested that it is inadequate to apply 
only the TNM staging system for participant selection in 
clinical trials, and that use of biomarkers will probably 
enhance the power of future clinical trials to obtain 
positive results. Our study provided a new insight into 
the change in the current international practice guidelines 
of non-metastatic NPC treated with IMRT. Personalized 
treatment intensification should be considered for those 
who show early serological signs of relapse, which should 
be confirmed in prospective randomized-controlled trials.
In conclusion, early serial undetectable plasma EBV 
DNA titers after radical IMRT with or without adjunct 
chemotherapy were prognostic of better 3-year survival 
outcomes in patients with non-metastatic nasopharyngeal 
carcinoma.
MATERIALS AND METHODS
Study design and population
Patients with newly diagnosed non-metastatic 
NPC of undifferentiated type (WHO Type III) treated 
with IMRT as a curative treatment were recruited into 
this prospective observational study since July 2010 
with prior approval by the local institutional review 
board of our institution. The study was undertaken in 
accordance with Declaration of Helsinki and Good 
Clinical Practice guidelines. After written informed 
consent, all patients had pretreatment workup including 
serum hematology and biochemistry, plasma EBV DNA, 
[18F]fluorodeoxyglucose (18F-FDG) positron-emission 
tomography with integrated contrast-enhanced computed 
tomography (PET-CT) scan with patients immobilized by 
a prefabricated customized head and neck thermoplastic 
cast, and magnetic resonance imaging (MRI) including 
T1, T2 and fat-suppressed contrast-enhanced T1 
sequences of the head and neck in treatment position by 
3T scanner (Arhieva 3.0 T, Philips Healthcare, Best, The 
Netherlands) on the following day as previously described 
to exclude those with distant metastasis or second primary 
malignancy and for IMRT target delineation and planning 
(Supplementary Data). Two independent radiologists 
specialized in head and neck radiology and blinded to 
treatment details determined the stage and tumor extent; 
any discrepancies were resolved by consensus, based on 
the 7th edition of AJCC classification. Plasma EBV DNA 
was extracted and calculated as previously described 
(Supplementary Data) [12]. All patients also underwent 
endoscopy and nasopharyngeal biopsies on both sides of 
the nasopharynx to assess extent of mucosal tumor spread. 
Then they received IMRT as described (Supplementary 
Data) [38]. Briefly, 70 Gy was delivered to the planning 
target volume (PTV)-70 and 66 Gy to the PTV-66 in 33 
fractions by the simultaneous accelerated radiation therapy 
technique. In general, patients with stage I and II disease 
received IMRT alone while stage III to IVB patients 
received concurrent chemoradiation with the Intergroup 
0099 regimen consisting of cisplatin intravenous infusion 
(100mg/m2) every three weeks starting on the 1st day 
of IMRT and adjuvant chemotherapy with cisplatin on 
day 1 and 5-FU from day 1 to 4 for three more cycles 
starting at four weeks following IMRT [39]. Patients with 
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bulky cervical nodal (≥3cm in diameter) stage II disease 
were also given concurrent chemoradiation only, at the 
discretion of the treating oncologist. Patients who had 
their primary tumors in close proximity to normal critical 
organs-at-risk (OARs) would receive 3 cycles of induction 
chemotherapy (cisplatin 100mg/m2 on day 1 and 5-FU 
1000mg/m2 from day 1 to 5 every three weeks) before 
concurrent chemoradiation, in an attempt for significant 
tumor shrinkage so that a radical radiation dose could be 
delivered to the tumors with more sparing of these OARs. 
At 8 weeks following completion of IMRT, all patients 
had routine 6-site random nasopharyngeal biopsies as our 
standard practice and blood checked for plasma EBV DNA 
titers (Figure 1) [40]. Local salvage treatment was given 
to patients who had persistent primary tumor at 12 weeks 
after IMRT [41]. If their plasma EBV DNA was still >0 
copies/ml at 8 weeks after IMRT, it would be repeated 4 
weeks thereafter until it was undetectable or it was proven 
to have persistent locoregional disease or metastasis 
clinically or radiologically. Patients with complete local 
remission had follow up clinical evaluation every 2 to 3 
months, surveillance MRI scan every 3 to 4 months, and 
PET-CT scan if clinically suspicious of relapse. Plasma 
EBV DNA was measured again at 6 months after IMRT 
and then as clinically indicated afterwards. Any elevation 
of plasma EBV DNA would lead to endoscopy and 
nasopharyngeal biopsy, MRI and PET-CT evaluation and 
subsequent salvage treatment if recurrence was confirmed.
Statistical analysis
The prespecified survival endpoints including 
local failure-free survival (LFFS), regional failure-
free survival (RFFS), distant metastasis-free survival 
(DMFS), progression-free survival (PFS), cancer-
specific survival (CSS) and overall survival (OS) were 
defined and evaluated by log rank tests (Supplementary 
Data). Univariable and multivariable analyses by 
Cox proportional hazard models were employed for 
identifying prognostic factors for these survival endpoints 
with age, sex, Eastern Cooperative Oncology Group 
(ECOG) performance status (PS), T-classification, 
N-classification, overall stage of NPC, IMRT alone 
versus chemoradiation, concurrent chemoradiation only, 
induction chemotherapy then concurrent chemoradiation, 
concurrent chemoradiation then adjuvant chemotherapy 
and baseline and post-IMRT 8th week and 6th month 
undetectable plasma EBV DNA titers as covariates. Time-
dependent receiver-operating characteristics (TDROC) 
analyses were performed to obtain time-dependent 
concordance indices (Ct) and area under the curve (AUC) 
for advanced stage IVA to IVB disease versus stage I to 
III disease [42]. Nonparametric bootstrapping with 1000 
replicates was also used to determine 95% confidence 
interval (CI) of the Ct and to evaluate the difference in 
Ct indices between these disease groups. TDROC was 
performed by the statistical software package R version 
3.1.3 [43]. The other statistical analyses were performed 
by Statistical Package for Social Sciences (SPSS) version 
20. Tests were considered statistically significant at P < 
0.05 (two-sided). The database-lock date for analysis was 
December 30, 2015.
This study was presented in part as an oral abstract 
at 51st American Society of Clinical Oncology (ASCO) 
Annual Meeting (Abstract 6007), Chicago, IL, May 29-
June 2, 2015. Clinical trial information: NCT02476669 
(ClincalTrials.gov).
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